Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Becton Dickinson and Co (NYSE:BDX)

Delayed Data
As of Oct 05
 +1.62 / +1.20%
Today’s Change
Today|||52-Week Range
Health Technology
Medical Specialties

Company Description

Becton, Dickinson & Co. is a global medical technology company. The company is engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. The company operates through three worldwide business segments: BD Medical, BD Diagnostics and BD Biosciences. The BD Medical segment produces medical devices that are used in a wide range of healthcare settings. This segment product include needles, syringes and intravenous catheters for medication delivery; prefilled IV flush syringes; syringes and pen needles for the self-injection of insulin and other drugs used in the treatment of diabetes. The BD Diagnostics segment provides products for the safe collection and transport of diagnostics specimens, as well as instrument systems and reagents to detect a broad range of infectious diseases, healthcare-associated infections and cancers. This segment products include integrated systems for specimen collection; safety-engineered blood collection products and systems; automated blood culturing systems; molecular testing systems for infectious diseases and women's health; microorganism identification and drug susceptibility systems; liquid-based cytology systems for cervical cancer screening; rapid diagnostic assays; microbiology laboratory automation; and plated media. The BD Biosciences segment produces research and clinical tools that facilitate the study of cells, and the components of cells, to gain a better understanding of normal and disease processes. This segment product include fluorescence-activated cell sorters and analyzers; monoclonal antibodies and kits for performing cell analysis; reagent systems for life science research; cell imaging systems; diagnostic assays; and cell culture media supplements for biopharmaceutical manufacturing. Becton, Dickinson & Co. was founded by Maxwell W. Becton and Fairleigh S. Dickinson in 1897 and is headquartered in Franklin Lakes, NJ.

Contact Information

Becton, Dickinson & Co.
1 Becton Drive
Franklin Lakes New Jersey 07417-1880
P:(201) 847-6800
Investor Relations:
(201) 847-5378



Mutual fund holders43.69%
Other institutional42.26%
Individual stakeholders0.81%

Top Executives

Vincent A. ForlenzaChairman, President & Chief Executive Officer
William A. KozyChief Operating Officer & Executive Vice President
Christopher R. ReidyChief Financial Officer & EVP-Administration
Ellen R. StrahlmanChief Medical Officer, SVP-Research & Development
Susan MoreiraDirector-Research & Development